HONG KONG – Shenyang, China-based 3Sbio Inc. has signed a partnership agreement with Verseau Therapeutics Inc., of Lexington, Mass., to develop and commercialize monoclonal antibodies in the field of immuno-oncology for a broad range of cancers. The collaboration will be based on Verseau's drug discovery platform, which generates first-in-class macrophage checkpoint modulators (MCMs) to treat patients with cancer, immune and inflammatory diseases.